GLP-1 Drugs Prompt New Food Offerings
The success of new obesity and diabetes drugs is evident in grocery store aisles as food manufacturers introduce GLP-1-friendly products.
GLP-1 Agonist Drugs Show Promise for Treating More Conditions
GLP-1 agonist drugs like Ozempic, Wegovy, Mounjaro, and Zepbound are showing promise for treating various conditions beyond their original scope.
GLP-1 Weight Loss Drugs in the News, Again
Let’s take a look at the latest headlines to glimpse at what’s happening in the world of weight loss meds.
Can You Stop Taking Anti-Obesity Drugs?
The debate centers on whether treating obesity as a chronic disease means patients should remain on these drugs long-term or if they can eventually stop.
The New Drugs and Unforeseen Consequences, Continued
Death and drinking are two more areas that interact with GLP-1 drugs and their cousins. But failing to treat obesity can also lead to suicide.
The New Drugs and Unforeseen Consequences
A discouraging number of lawsuits involving the new weight-loss drugs are currently underway, with potentially thousands more waiting in the wings.
Views on New Drugs Vary
The new weight-loss meds do not treat the root causes of obesity, just like asthma drugs don’t treat air quality and pain relievers don’t prevent injury.
New Drugs — Does Lifestyle Intervention Still Count? Part 5
To put it bluntly, weight loss drugs don’t work unless the patient is also involved in some aspect of what the drug makers define as intervention.
New Drugs — Does Lifestyle Intervention Still Count? Part 4
Do the new, remarkably effective GLP-1 obesity medications eliminate the need for obesity interventions such as the BrainWeighve app?
New Drugs — Does Lifestyle Intervention Still Count? Part 3
Tirzepatide, a medication combining semaglutide with another GLP-1 agonist, known as Mounjaro, is approved for type 2 diabetes but widely used for weight loss.